# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4418811 | B | Inhibition of C-terminal FLAG-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged human BMP1 (121 to 721 amino acids) expressed in CHO-E1a cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 60 mins using 0.5 nM BMP1 by FRET based assay | Homo sapiens | 144 | cell-based format | Patent Bioactivity Data | ||
2. | ALA4418812 | B | Inhibition of C-terminal FLAG-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged human BMP1 (121 to 721 amino acids) expressed in CHO-E1 cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 30 mins using 50 nM BMP1 by FRET based assay | Homo sapiens | 144 | cell-based format | Patent Bioactivity Data | ||
3. | ALA4418813 | B | Inhibition of recombinant human TLL1 I156V/N221S/V284A mutant expressed in CHOE1A cells pre-incubated for 10 mins before promyostatin peptide substrate addition and measured after 60 mins by FRET based assay | Homo sapiens | 140 | cell-based format | Patent Bioactivity Data | ||
4. | ALA4418814 | B | Inhibition of C-terminal Avi-6x-His epitope tagged and N-terminal human RAGE signal sequence tagged recombinant human TLL2 (26 to 1015 amino acids) expressed in CHOE1A cells incubated for 60 mins with promyostatin peptide substrate by FRET based assay | Homo sapiens | 138 | cell-based format | Patent Bioactivity Data | ||
5. | ALA4418815 | F | Reduction in PICP levels in human cardiac fibroblasts incubated for 24 to 48 hrs by ELISA | Homo sapiens | 112 | assay format | Patent Bioactivity Data | ||
6. | ALA4418816 | F | Reduction in mature collagen deposition levels in human cardiac fibroblasts incubated for 24 to 48 hrs by immunostaining based assay | Homo sapiens | 27 | assay format | Patent Bioactivity Data | ||
7. | ALA4418819 | A | Drug metabolism in heparinized pooled human plasma at pH 7.5 assessed as formation of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid at 100 to 2000 ng/ml incubated up to 4 or 24 hrs by by LC-MS/MS analysis | Homo sapiens | 39 | cell-free format | Patent Bioactivity Data |